The management of venous thromboembolism in hospitalized patients with COVID-19.
Reads0
Chats0
TLDR
It is raised the possibility that intermediate or weight-based heparin dosing may be more effective than fixed dosing for thromboprophylaxis in high-risk subsets of patients hospitalized with COVID-19, and ongoing randomized trials that address key clinical questions have the potential to reduce the morbidity and mortality from VTE.About:
This article is published in Blood Advances.The article was published on 2020-08-25 and is currently open access. It has received 13 citations till now. The article focuses on the topics: Platelet activation.read more
Citations
More filters
Journal ArticleDOI
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
Inspiration Investigators,Parham Sadeghipour,Azita Hajhossein Talasaz,Farid Rashidi,Babak Sharif-Kashani,Mohammad Taghi Beigmohammadi,Mohsen Farrokhpour,Seyed Hashem Sezavar,Pooya Payandemehr,Ali Dabbagh,Keivan Gohari Moghadam,Sepehr Jamalkhani,Hossein Khalili,Mahdi Yadollahzadeh,Taghi Riahi,Parisa Rezaeifar,Ouria Tahamtan,Samira Matin,Atefeh Abedini,Somayeh Lookzadeh,Hamid Reza Rahmani,Elnaz Zoghi,Keyhan Mohammadi,Pardis Sadeghipour,Homa Abri,Sanaz Hariri Tabrizi,Seyed Masoud Mousavian,Shaghayegh Shahmirzaei,Hooman Bakhshandeh,Ahmad Amin,Farnaz Rafiee,Elahe Baghizadeh,Bahram Mohebbi,Seyed Ehsan Parhizgar,Rasoul Aliannejad,Vahid Eslami,Alireza Kashefizadeh,Hessam Kakavand,Seyed Hossein Hosseini,Shadi Shafaghi,Samrand Fattah Ghazi,Atabak Najafi,David Jiménez,Aakriti Gupta,Aakriti Gupta,Mahesh V. Madhavan,Sanjum S. Sethi,Sahil A. Parikh,Manuel Monreal,Naser Hadavand,Alireza Hajighasemi,Majid Maleki,Saeed Sadeghian,Gregory Piazza,Ajay J. Kirtane,Benjamin W. Van Tassell,Paul P. Dobesh,Gregg W. Stone,Gregory Y.H. Lip,Gregory Y.H. Lip,Harlan M. Krumholz,Samuel Z. Goldhaber,Behnood Bikdeli,Behnood Bikdeli +63 more
TL;DR: In this paper, the authors evaluated the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU).
Journal ArticleDOI
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.
Azita Hajhossein Talasaz,Parham Sadeghipour,Hessam Kakavand,Maryam Aghakouchakzadeh,Elaheh Kordzadeh-Kermani,Benjamin W. Van Tassell,Azin Gheymati,Hamid Ariannejad,Seyed Hossein Hosseini,Sepehr Jamalkhani,Michelle Sholzberg,Manuel Monreal,David Jiménez,Gregory Piazza,Sahil A. Parikh,Ajay J. Kirtane,John W. Eikelboom,Jean M. Connors,Beverley J. Hunt,Stavros Konstantinides,Mary Cushman,Jeffrey I. Weitz,Gregg W. Stone,Harlan M. Krumholz,Gregory Y.H. Lip,Samuel Z. Goldhaber,Behnood Bikdeli +26 more
TL;DR: In this paper, a variety of antithrombotic agents, doses, and durations of therapy are assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19.
Journal ArticleDOI
Multicenter registry of United States emergency department patients tested for SARS‐CoV‐2
Jeffrey A. Kline,Katherine L. Pettit,Christopher Kabrhel,D. Mark Courtney,Kristen E. Nordenholz,Carlos A. Camargo +5 more
TL;DR: The registry will provide a vital platform for characterizing the course, epidemiology, clinical features, and prognosis of patients tested for COVID‐19 in the ED setting, and the initial goals are to derive and test a pretest probability instrument for prediction of SARS‐CoV‐2 test results.
Posted ContentDOI
Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials
Azita Hajhossein Talasaz,Parham Sadeghipour,Hessam Kakavand,Maryam Aghakouchakzadeh,Benjamin W. Van Tassell,Elahe Kordzadeh-Kermani,Azin Gheymati,Hamid Ariannejad,Seyed Hossein Hosseini,Sepehr Jamalkhani,Sepehr Jamalkhani,Michelle Sholzberg,Michelle Sholzberg,Manuel Monreal,David Jiménez,Gregory Piazza,Sahil A. Parikh,Ajay J. Kirtane,John W. Eikelboom,Jean M. Connors,Beverley J. Hunt,Stavros Konstantinides,Stavros Konstantinides,Mary Cushman,Jeffrey I. Weitz,Gregg W. Stone,Harlan M. Krumholz,Gregory Y.H. Lip,Gregory Y.H. Lip,Samuel Z. Goldhaber,Behnood Bikdeli,Behnood Bikdeli +31 more
TL;DR: In this paper, the authors provide a perspective of the ongoing or completed randomized controlled trials related to antithrombotic strategies used in coronavirus disease-2019, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.
Journal ArticleDOI
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm
Paulina Niedźwiedzka-Rystwej,Adam Majchrzak,Sara Kurkowska,P. Małkowska,Olga Sierawska,Rafał Hrynkiewicz,Miłosz Parczewski +6 more
TL;DR: To develop methods of appropriate treatment and therefore decrease the mortality of the so-called COVID-19-CS, the authors need to look deeply inside its pathogenesis, which is the purpose of this review.
Related Papers (5)
A review of venous thromboembolism in COVID-19: A clinical perspective.
Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19
Paul P. Dobesh,Toby C. Trujillo +1 more